<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sintx Technologies Inc — News on 6ix</title>
<link>https://6ix.com/company/sintx-technologies-inc</link>
<description>Latest news and press releases for Sintx Technologies Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sintx-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c15b78dffbe2df118df0.webp</url>
<title>Sintx Technologies Inc</title>
<link>https://6ix.com/company/sintx-technologies-inc</link>
</image>
<item>
<title>SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-provides-corporate-business-update-highlighting-first-human-implant-strategic-transformation-and-commercial-execution</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-provides-corporate-business-update-highlighting-first-human-implant-strategic-transformation-and-commercial-execution</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah,</description>
</item>
<item>
<title>SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-first-in-human-surgery-using-fda-cleared-sinapticr-foot-and-ankle-implant</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-first-in-human-surgery-using-fda-cleared-sinapticr-foot-and-ankle-implant</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Major clinical milestone marks SINTX’s entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial</description>
</item>
<item>
<title>SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-appoints-ryan-elmore-133000530</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-appoints-ryan-elmore-133000530</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effec</description>
</item>
<item>
<title>SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-participate-noble-capital-140000326</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-participate-noble-capital-140000326</guid>
<pubDate>Thu, 29 Jan 2026 14:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period of operational restructur</description>
</item>
<item>
<title>SINTX Technologies to Participate in Sidoti & Company Investor Conference</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-participate-sidoti-company-140000862</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-participate-sidoti-company-140000862</guid>
<pubDate>Mon, 08 Dec 2025 14:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-o</description>
</item>
<item>
<title>SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-signs-supply-agreement-133000339</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-signs-supply-agreement-133000339</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation (“EVONIK”), a global leader in high‑performance polymers, to manufacture the Company’s proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for A</description>
</item>
<item>
<title>SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-reports-pivotal-third-quarter-130000879</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-reports-pivotal-third-quarter-130000879</guid>
<pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
<description>Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™ SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company’s Form 10-Q for the quarter ended September 30,</description>
</item>
<item>
<title>SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-launch-osseosculpt-130000202</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-launch-osseosculpt-130000202</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomedical applications of silicon nitride (Si₃N₄), today announced the execution of a private label agreement to supply OsseoSculpt™, a next-generation biologic designed to complement the Company’s FDA 510(K) cleared SINAPTIC® Foot & Ankle Osteoto</description>
</item>
<item>
<title>SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-receives-fda-clearance-110000559</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-receives-fda-clearance-110000559</guid>
<pubDate>Mon, 20 Oct 2025 11:00:00 GMT</pubDate>
<description>FDA cleared and U.S. manufactured implant system positions SINTX to enter billion-dollar U.S. market SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics specializing in biomedical applications of silicon nitride (Si₃N₄), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstruc</description>
</item>
<item>
<title>UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-strengthens-infection-prevention-portfolio-110000816</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-strengthens-infection-prevention-portfolio-110000816</guid>
<pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
<description>New U.S. Patent reinforces competitive advantage and enables broader licensing and product opportunities across key markets SALT LAKE CITY, Utah, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application containing method cl</description>
</item>
<item>
<title>SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-strengthens-ip-portfolio-110000034</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-strengthens-ip-portfolio-110000034</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>New method patent expands SINTX’s infection-prevention IP portfolio in $30 Billion Total Addressable Market U.S. Patent Notice of Allowance reinforces competitive advantage and enables broader licensing and product opportunities across key markets SALT LAKE CITY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the Unit</description>
</item>
<item>
<title>SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-present-h-c-110000097</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-present-h-c-110000097</guid>
<pubDate>Tue, 09 Sep 2025 11:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Utah, Sept. 09, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that it has been invited to present at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The Company’s presentation is scheduled for Tuesday, September 9, 2025. “</description>
</item>
<item>
<title>SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-successful-exercise-115400159</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-successful-exercise-115400159</guid>
<pubDate>Mon, 08 Sep 2025 11:54:00 GMT</pubDate>
<description>SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock of the Company originally issued in February 2025, having an exercise price of $3.32 per share. T</description>
</item>
<item>
<title>SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-receives-uspto-notice-110000090</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-receives-uspto-notice-110000090</guid>
<pubDate>Mon, 08 Sep 2025 11:00:00 GMT</pubDate>
<description>Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, “Antipathogenic Fibrous Materials.” The patent secures broad protection for SINTX’s proprietary silicon nitride–based antipathogen pla</description>
</item>
<item>
<title>SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-publishes-landmark-study-110000655</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-publishes-landmark-study-110000655</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the publication of a peer-reviewed study demonstrating that silicon nitride exhibits potent antiviral activity against multiple infectious virus strains, including SARS-CoV-2 an</description>
</item>
<item>
<title>SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-issues-business-following-110000642</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-issues-business-following-110000642</guid>
<pubDate>Fri, 15 Aug 2025 11:00:00 GMT</pubDate>
<description>Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and availab</description>
</item>
<item>
<title>SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-expands-silicon-nitride-110000782</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-expands-silicon-nitride-110000782</guid>
<pubDate>Mon, 04 Aug 2025 11:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Utah, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for musculoskeletal applications, today announced the publication of a peer-reviewed study in the Journal of the Mechanical Behavior of Biomedical Materials. The study validates the use of silicon nitride (Si₃N₄) surface coatings on carbon fiber–reinforced polyetherketoneketone (CFR-PEKK) trauma plates—m</description>
</item>
<item>
<title>SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-submits-fda-510-110000727</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-submits-fda-510-110000727</guid>
<pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
<description>Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market SALT LAKE CITY, Utah, July 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical applications, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its novel silicon nitride osteotom</description>
</item>
<item>
<title>SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-acquires-sinaptic-surgical-123000927</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-acquires-sinaptic-surgical-123000927</guid>
<pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
<description>Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic man</description>
</item>
<item>
<title>SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors</title>
<link>https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-strategic-vision-130000296</link>
<guid isPermaLink="true">https://6ix.com/company/sintx-technologies-inc/news/sintx-technologies-announces-strategic-vision-130000296</guid>
<pubDate>Thu, 12 Jun 2025 13:00:00 GMT</pubDate>
<description>New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of</description>
</item>
</channel>
</rss>